REFILE-BUZZ-Acelyrin slides after reiterating merger with Alumis amid Concentra's buyout offer

Reuters03-04

Corrects company name to "Concentra" in bullet 3, corrects typographical error in bullet 5

** Shares of drug developer Acelyrin SLRN.O fall 12.7% to $2.30

** SLRN reiterates its planned merger with Alumis, says unsolicited buyout offer from Concentra Biosciences is not expected to result in superior proposal

** Concentra last month offered to buy Acelyrin for about $300 million, according to Reuters calculations

** SLRN early in February agreed to merge with Alumis in all-stock transaction

** Transaction is expected to close by Q2 2025

** SLRN stock has fallen 67.3% in past 12 months

(Reporting by Padmanabhan Ananthan)

((Padmanabhan.Ananthan@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment